Novartis' Iptacopan (LNP023) Receives the US FDA's Breakthrough Therapy Designation for PNH and Rare Pediatric Disease Designation for C3G
Shots:
- The US FDA has granted BTD in paroxysmal nocturnal hemoglobinuria and RPDD in C3 glomerulopathy
- The BTD is based on results from two ongoing P-II studies- where iptacopan showed benefits both in patients who remained anemic and dependent on transfusions despite SOC anti-complement treatment as well as monothx. in anti-C5 naïve PNH patients
- Iptacopan is a first-in-class- orally administered- potent and highly selective factor B inhibitor of the alternative complement pathway with its first FDA filing anticipated in 2023
Ref: Novartis | Image: Novatis
Click here to read the full press release
Tags
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com